This shift in focus is crucial for development of novel therapeutic approaches, since considerable experimental evidences indicated that changes in APP metabolism can be the common pathogenic process in different alleged causes of Alzheimer's disease [8], [10], [32], [37]–[49], [58]. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.